Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AVENUE THERAPEUTICS, INC.

(ATXI)
  Report
Delayed Nasdaq  -  04:00:00 2023-03-24 pm EDT
1.060 USD   +0.95%
03/09North American Morning Briefing: Stock Futures Dip as Higher Rate Fears Persist
DJ
03/08Avenue Therapeutics Shares Jump 33% on Upcoming FDA Meeting on Opioid Stacking Study Risks
DJ
03/08Avenue Therapeutics, Inc. : Change in Directors or Principal Officers, Shareholder Director Nominations, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2023 03/21/2023 03/22/2023 03/23/2023 03/24/2023 Date
1.06(c) 1.05(c) 1.06(c) 1.05(c) 1.06(c) Last
127 726 102 136 128 542 118 975 122 004 Volume
-4.50% -0.94% +0.95% -0.94% +0.95% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Sales 2023 - - -
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -
Yield 2023 -
Capitalization 7,92 M 7,92 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 4
Free-Float 86,8%
More Financials
Company
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company seeks to develop and commercialize its product principally for use in the acute/intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, for the treatment of post-operative acute pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works... 
More about the company
All news about AVENUE THERAPEUTICS, INC.
03/09North American Morning Briefing: Stock Futures Dip as Hi..
DJ
03/08Avenue Therapeutics Shares Jump 33% on Upcoming FDA Meeting on Opioid Stacking Study Ri..
DJ
03/08Avenue Therapeutics, Inc. : Change in Directors or Principal Officers, Shareholder Directo..
AQ
03/08Avenue Therapeutics, Inc. Announces Board Changes
CI
03/08Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updat..
AQ
03/02Avenue Therapeutics Signs License Agreement to Develop, Commercialize Kennedy's Disease..
MT
03/02Avenue Therapeutics, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale ..
AQ
03/02Avenue Therapeutics, Inc. Enters into A License Agreement with Annji Pharmaceutical Co...
CI
03/02Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmac..
AQ
02/10Avenue Therapeutics, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Yea..
AQ
02/03Avenue Therapeutics, Inc. : Change in Directors or Principal Officers, Amendments to Artic..
AQ
02/01Avenue Therapeutics, Inc. : Entry into a Material Definitive Agreement, Unregistered Sale ..
AQ
01/31Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Pl..
AQ
01/31Avenue Therapeutics, Inc. announced that it has received $0.24 million in funding
CI
01/30Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Pri..
AQ
More news
News in other languages on AVENUE THERAPEUTICS, INC.
03/09Wall Street hard onderuit in aanloop naar banencijfer
03/09Wall Street zakt weg
03/09Futloze stemming op Wall Street
03/09Futures Wall Street wijzen omlaag
03/08Avenue Therapeutics, Inc. annonce des changements au sein de son conseil d'administrati..
More news
Analyst Recommendations on AVENUE THERAPEUTICS, INC.
More recommendations
ETFs positioned on AVENUE THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Vanguard Extended Market ETF - USD0%0.21%United_States
More ETFs positioned on AVENUE THERAPEUTICS, INC.
Chart AVENUE THERAPEUTICS, INC.
Duration : Period :
Avenue Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AVENUE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1,06 $
Average target price 32,00 $
Spread / Average Target 2 919%
Managers and Directors
Alexandra MacLean Chief Executive Officer & Director
David Jin Secretary, Chief Operating & Financial Officer
Jay D. Kranzler Chairman
Scott A. Reines Chief Medical Officer
Neil Herskowitz Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AVENUE THERAPEUTICS, INC.-8.62%8
REGENERON PHARMACEUTICALS, INC.13.65%87 515
VERTEX PHARMACEUTICALS8.87%80 827
WUXI APPTEC CO., LTD.-1.06%34 805
BIONTECH SE-14.66%31 155
GENMAB A/S-12.34%24 291
Stock markets for all
100% Free Registration
fermer